Sarcopenia leads to muscle weakness and greatly affects physical activity and the quality of life of elderly individuals [6, 7] ; sarcopenia is common in elderly people, and is estimated to occur in 5-13% of people aged 60-70 years and in 11-50% of those ≥80 years [8] . The mechanisms of sarcopenia development are actively being studied and involve both intrinsic and extrinsic factors, including the decline of satellite cell activation, altered hormonal status, contraction-induced injury, cellular vacuolization, autophagy, apoptosis and increased oxidative stress [9] . Mouse C2C12 skeletal muscle cells are an in vitro model that is widely used to study the factors that regulate muscle growth, proliferation and differentiation [10] . The differentiation of myotubes can be induced by 2% fetal bovine serum (FBS) . Previous studies have demonstrated that C2C12 myoblasts cultured in a growth-factor-deficient state causes the mononucleated myoblasts to exit the cell cycle, which activates the expression of genes that promote myoblast fusions and the formation of multi-nucleated myotubes [11, 12] . During this process, changes in cell shape along with cell fusion occur, and myotube phenotypes can be observed within 5-6 days. In addition, when muscle fiber formation (myogenesis) begins, myogenic transcriptional regulatory factors belonging to the MyoD family, including MyoD, myogenin, Myf4 and Myf5, are activated [13] . Amongst these, myogenin has an important role within the MyoD family as it regulates the differentiation of single nucleated myoblasts into multinucleated myofibers [14] . Glucocorticoids are important in the development of muscle atrophy in humans and animals. In both in vivo and in vitro experiments, muscle atrophy is induced by synthetic glucocorticoids such as dexamethasone (DEX) [15] . In skeletal muscles, DEX causes a reduction in protein synthesis and an increase in protein degradation through the ubiquitinproteasome pathway [16] . The ubiquitin-proteasome pathway has been revealed to mediate the degradation of short-lived proteins and long-lived myofibrillar proteins [17] . This protein-degradation system comprises three enzymatic components: the ubiquitin-activating E1 enzyme, the ubiquitinconjugating E2 enzyme and the ubiquitin-ligating E3 enzyme. E3 ubiquitin ligases serve a crucial role in identifying and targeting proteins for proteasomal degradation [17, 18] . A previous study characterized two muscle-specific E3 ubiquitin ligases, muscle RING-finger 1 (MuRF1) and muscle atrophy F-box (MAFbx; also known as atrogin1), as markers of skeletal muscle atrophy. Levels of MuRF1 and atrogin1/MAFbx expression are induced early in the atrophy process, prior to the loss of muscle mass [19] . The expression of atrogin1/MAFbx is controlled by forkhead box O, whereas MuRF1 transcription is controlled by nuclear factor-κB (NF-κB) [20] .
The present study investigated the potential protective effects of FTJ on DEX-induced muscle atrophy in C2C12 mouse skeletal muscle cells, based on the efficacy of FTJ muscle contraction and release. The anti-atrophy potential of FTJ was determined by focusing on its effects on the expression of atrogin-1/MAFbx and MuRF1.
Materials and Methods Preparation of FTJ Extracts
The fruits of Trapa japonica (FTJ) were air-dried at room temperature and ground to powder using a mechanical grinder. Approximately 5 g of the powder was then added to 300 ml 70% ethanol and stirred continuously at 100 rpm for 24 h at room temperature. The resulting extract was filtered and the solvent was removed by rotary vacuum evaporation (N-1200S; EYELA, Tokyo, Japan). The extract was then dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich Chemical Co., St. Louis, MO, USA) to obtain a 25 mg/ml stock solution and stored at 4℃. This solution was diluted to the desired concentration with physiological saline prior to use.
Cell culture and MTT assay C2C12 mouse skeletal muscle cells were obtained from the American Type Culture Collection (Rockville, MD, USA) and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillinstreptomycin at 37℃ in a humidified chamber containing 95% air and 5% CO2. For the cell viability assay, cells were cultured in the absence and presence of various concentrations of FTJ for 24 h. Measurement of cell viability was determined using the MTT assay, which is based on the conversion of MTT to MTT-formazan by mitochondrial enzymes. Induction of differentiation. C2C12 myoblasts were grown to 70-80% confluence in culture dishes at 37˚C, trypsinized and seeded (3x104 cells/well) into 6-well culture plates for experiments. Cells were grown to 70-80% confluence in DMEM supplemented with 10% FBS at 37˚C for 24 h, at which time the medium was replaced with DMEM containing 2% FBS to induce myotube differentiation; the medium was replaced every 2 days. Cells were allowed to differentiate for 6 days, at which point 90% of the cells had fused into myotubes.
Treatment with DEX and FTJ Following 6 days of differentiation, C2C12 myotubes were treated with 10, 50 or 100 μM DEX at 37˚C for 24 h for concentration screening. The C2C12 myotubes were subdivided into four groups: i) the control group, in which cells were incubated in serum free medium (SFM; DMEM containing 100 U/ml penicillin and 100 mg/ml streptomycin); ii) the DEX group, in which cells were treated with 100 μM DEX; iii) the DEX+FTJ group, in which cells were treated with 100 μM DEX and 80 μg/ml FTJ; and iv) the FTJ group, in which cells were treated with 80 μg/ml FTJ. All groups were incubated at 37˚C for 24 h, prior to harvesting cells for experiments.
Measurement of myotube diameter
Images of myotube cultures were captured with a phase contrast microscope set to x100 magnification at 2, 4, 5 and 6 days following induction of differentiation. Images of myotube cultures were also captured following treatment with DEX (100 μM) and/or FTJ (80 μg/ml) for 24 h.
A total of 50 myotube diameters from at least 10 random fields were measured using ImageJ software (version 4.16; National Institutes of Health, Bethesda, MD, USA).
Protein extraction and western blot analysis
Cells were harvested and lysed with lysis buffer (20 mM sucrose, 1 mM EDTA, 20 μM Tris-HCl, pH 7.2, 1 mM DTT, 10 mM KCl, 1.5 mM MgCl2 and 5 μg/ml aprotinin) for 30 min. The protein concentration was measured using a Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). For western blot analysis, an equal quantity of protein was subjected to electrophoresis on sodium dodecyl sulfate (SDS)polyacrylamide gel and transferred to a nitrocellulose membrane (Schleicher & Schuell, Inc., Keene, NH, USA). Blots were probed with the desired antibodies for 1 h, incubated with the diluted enzyme-linked secondary antibody and visualized by enhanced chemiluminescence according to the manufacturer's instructions (Amersham Pharmacia Biotech). MAFbx, muscle atrophy F-box; MuRF1, muscle RING finger 1. Table 3 . RT-PCR reactions were incubated for an initial denaturation at 95℃ for 10 min, followed by 40 cycles of: 95℃ for 15 sec, 55℃ for 15 sec, and 72℃ for 15 sec. Amplification products obtained by PCR were electrophoretically separated on 1% agarose gel and visualized by EtBr staining. 
Statistical analysis
The data are expressed as the mean ± SD. A statistical comparison was performed using one-way analysis of variance followed by Fisher's exact test. The significant differences between the groups were determined using unpaired Student's t-test. p < 0.05 was considered to indicate a statistically significant difference.
Results

Confirmation of C2C12 myotube differentiation
C2C12 skeletal muscle myoblasts were induced to differentiate in a mitogen poor media such as 2% FBS, fusing to form multinucleate myotubes [21] . Fig. 1 illustrates that the cell diameter remained similar following 2, 4, 5 and 6 days of differentiation. In addition, the level of myogenin expression, a factor that regulates terminal differentiation of muscle cells, was similar following 2, 4 and 5 days then increased following 6 days. These results indicate complete differentiation of myoblasts into myotubes at this time (6 days). 
DEX induced muscle atrophy in C2C12 myotubes
MuRF1 and atrogin1/MAFbx protein expression levels were measured in C2C12 myotubes treated with DEX (10, 50 or 100 μM) for 24 h ( Fig. 2A and B) . Treatment with DEX led to increased protein expression levels for MuRF1 and atrogin1/MAFbx, and the levels of expression increased in a dose dependent manner. These data suggest that DEX may induce muscle atrophy in C2C12 myotubes. In addition, as shown in Fig. 2C , when compared with the control group, the C2C12 myotube was markedly atrophied in the 100 μM DEX treated group. Therefore, all further experiments were performed following treatment with 100 μM DEX.
Toxicity of FTJ in C2C12 myoblast
The MTT assay was used to determine FTJ cytotoxicity to C2C12 myoblasts, which demonstrated no cytotoxic effects following FTJ treatment for 24 h (Fig. 3) . Therefore, all further experiments were performed 24 h following treatment with FTJ (80 μg/ml), which is the optimum concentration without toxicity as described by Choi et al. [22] .
Inhibitory effect of FTJ on DEX induced myotube atrophy C2C12 myotubes were allowed to differentiate for 6 days, followed by DEX (100 μM) and/or FTJ (80 μg/ml) treatment for a further 24 h. As a result, when compared with the control group, the DEX treated group exhibited a 52% reduction in cell diameter, whereas the FTJ treated group exhibited a 5% increase in cell diameter. In addition, DEX induced reduction of cell diameter was suppressed by co treatment with FTJ ( Fig. 4A and B) . The anti-atrophic effects of FTJ were investigated by examining the protein and mRNA expression levels of the muscle atrophy markers MuRF1 and atrogin1/MAFbx in C2C12 myotubes that were treated with DEX (100 μM) and FTJ (80 μg/ml) for 24 h ( Fig. 5 A and B ). Cells treated with DEX alone exhibited a marked increase in the mRNA and protein expression levels of MuRF1 and atrogin1/MAFbx compared with cells in the untreated control group ( Fig. 5 A and B) . The DEX induced upregulation of MuRF1 and atrogin1/MAFbx was suppressed by co treatment with FTJ (80 μg/ml). Therefore, FTJ may be able to inhibit atrophy and induce hypertrophy pathways in C2C12 myotubes. 
Discussion
Skeletal muscle atrophy refers to the decline in muscle mass and strength that may occur as a result of various conditions, including denervation, injury, glucocorticoid treatment, starvation, cancer, joint immobilization, sepsis and aging [23] . The present study focused on the progression of muscle atrophy caused by aging.
In the present study, anti-atrophic effects of the fruits of Trapa japonica (FTJ) were investigated in C2C12 myotubes. C2C12 mouse skeletal muscle cells are commonly used as a model for myotube differentiation to examine the signaling pathways involved in muscle atrophy. The effects of the FTJ on the muscle atrophy in C2C12 myotubes were determined by first culturing C2C12 myoblasts in media containing 2% FBS for 6 days to induce differentiation. Following differentiation, muscle atrophy was induced by treating the cells with DEX. DEX treatment has been previously demonstrated to reduce muscle mass, largely owing to the breakdown of muscle proteins due to upregulated catabolism by the ubiquitin prote¬asome system [24, 25] . Administration of high concentrations of DEX has been revealed to cause muscle atrophy in animals and humans [26] .
Results from the present study demonstrated that C2C12 myotubes respond to increasing concentrations of DEX (10, 50 and 100 μM) in a dose dependent manner, as revealed by the increased expression of MuRF1 and atrogin1/MAFbx protein levels. Prior to determining the protective effects of FTJ on muscle atrophy, the potential toxicity of FTJ on C2C12 myoblasts was determined using an MTT assay, which revealed that FTJ treatment had no cytotoxic effects on C2C12 myoblasts. We next assessed the protective effects of FTJ by measuring myotube diameter. Compared with the control group, the DEX treated group exhibited a 52% reduction in cell diameter, whereas the FTJ treated group exhibited a 5% increase in cell diameter. Subsequently, the effects of FTJ on C2C12 myotube atrophy were investigated by examining the expression levels of muscle atrophy markers MuRF1 and atrogin1/MAFbx, as they are upregulated in a number of catabolic conditions [27] . Glucocorticoids such as DEX have been demonstrated to promote myosin heavy chain degradation through the activation of the E3 ligase MuRF1 [28] .
